Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2025 Apr 2;9(4):e70105.
doi: 10.1002/hem3.70105. eCollection 2025 Apr.

High-dose therapy followed by autologous stem cell transplantation emerges as the preferred salvage therapy in patients with limited-stage Hodgkin lymphoma progressing/relapsing after initial therapy: A subset analysis of the EORTC/LYSA/FIL H10 trial

Gotti Manuel  1 , Yana Stepanishyna  2 , Tetiana Skrypets  3 , Luigi Marcheselli  4 , Caterina Cristinelli  5 , Barbara Botto  6 , Sanne Tonino  7 , Doriane Cavalieri  8 , Alessandro Pulsoni  9 , Martin Hutchings  10 , Mohammad Hammoud  11 , Catherine Fortpied  12 , Luigi Rigacci  13 , Wouter Plattel  14 , Marc André  15 , Massimo Federico  16
Affiliations

High-dose therapy followed by autologous stem cell transplantation emerges as the preferred salvage therapy in patients with limited-stage Hodgkin lymphoma progressing/relapsing after initial therapy: A subset analysis of the EORTC/LYSA/FIL H10 trial

Gotti Manuel et al. Hemasphere. .
No abstract available

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflicts of interest.

Figures

Figure 1
Figure 1
Sankey diagram. ABVD, doxorubicin, bleomycin, vinblastine, and dacarbazine; BEACOPP, bleomycin, etoposide, doxorubicin, cyclophosphamide, vincristine, procarbazine, and prednisone; HDCT, high‐dose chemotherapy; INRT, involved‐node radiotherapy; SCT, stem cell transplant; A1, 3 ABVD + INRT; A2, 3 ABVD; B1, 4‐ABVD ± INRT; B2, 6 ABVD; C1, 3 or 4 ABVD + INRT; C2, 2 AVBD + 2 escBEACOPP + INRT.
See this image and copyright information in PMC

References

    1. Federico M, Fortpied C, Stepanishyna Y, et al. Long‐term follow‐up of the response‐adapted intergroup EORTC/LYSA/FIL H10 trial for localized Hodgkin lymphoma. J Clin Oncol. 2024;42(1):19‐25. 10.1200/JCO.23.01745 - DOI - PMC - PubMed
    1. André MPE, Girinsky T, Federico M, et al. Early positron emission tomography response‐adapted treatment in stage I and II Hodgkin lymphoma: final results of the randomized EORTC/LYSA/FIL H10 trial. J Clin Oncol. 2017;35:1786‐1794. 10.1200/JCO.23.01745. - DOI - PubMed
    1. Radford J, Illidge T, Counsell N, et al. Results of a trial of PET‐directed therapy for early‐stage Hodgkin's lymphoma. N Engl J Med. 2015;372(17):1598‐1607. 10.1056/NEJMoa1408648 - DOI - PubMed
    1. Eich HT, Diehl V, Görgen H, et al. Intensified chemotherapy and dose‐reduced involved‐field radiotherapy in patients with early unfavorable Hodgkin's lymphoma: final analysis of the German Hodgkin Study Group HD11 trial. J Clin Oncol. 2010;28(27):4199‐4206. 10.1200/JCO.2010.29.8018 - DOI - PubMed
    1. Behringer K, Goergen H, Hitz F, et al. Omission of dacarbazine or bleomycin, or both, from the ABVD regimen in treatment of early‐stage favourable Hodgkin's lymphoma (GHSG HD13): an open‐label, randomised, non‐inferiority trial. Lancet. 2015;385(9976):1418‐1427. 10.1016/S0140-6736(14)61469-0 - DOI - PubMed

LinkOut - more resources